Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
about
RanBP2 modulates Cox11 and hexokinase I activities and haploinsufficiency of RanBP2 causes deficits in glucose metabolismNeuroprotection by pharmacologic blockade of the GAPDH death cascadeNitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of CocaineAntidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradationS-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 bindingEthanol and Acetaminophen Synergistically Induce Hepatic Aggregation and TCH346-Insensitive Nuclear Translocation of GAPDHDopamine neuron stimulating actions of a GDNF propeptideFKBP36 is an inherent multifunctional glyceraldehyde-3-phosphate dehydrogenase inhibitor.Proteomic approaches to quantify cysteine reversible modifications in aging and neurodegenerative diseases.Recent trends in protein biochip technology.An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron diseaseDevelopment and Implementation of a High Throughput Screen for the Human Sperm-Specific Isoform of Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDHS).Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer questionProtein S-nitrosylation in health and disease: a current perspective.Drug affinity responsive target stability (DARTS) for small-molecule target identification.Characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase early amyloid-like oligomers and their implication in α-synuclein aggregation.Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders.High Glucose-induced Retinal Pericyte Apoptosis Depends on Association of GAPDH and Siah1.Protein S-Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases.Nuclear translocation and accumulation of glyceraldehyde-3-phosphate dehydrogenase involved in diclazuril-induced apoptosis in Eimeria tenella (E. tenella).Progress in neuroprotection in Parkinson's disease.Protection against Parkinson's disease progression: clinical experience.Nuclear GAPDH: changing the fate of Müller cells in diabetes.Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity.CIB1 prevents nuclear GAPDH accumulation and non-apoptotic tumor cell death via AKT and ERK signaling.Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb.Development and validation of a screening assay for the evaluation of putative neuroprotective agents in the treatment of Parkinson's disease.Anti-apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells.Uncoupling oxidative/energy metabolism with low sub chronic doses of 3-nitropropionic acid or iodoacetate in vivo produces striatal cell damage.N8-acetyl spermidine protects rat cerebellar granule cells from low K+-induced apoptosis.Biological targets for isatin and its analogues: Implications for therapy.Glyceraldehyde-3-phosphate dehydrogenase tetramer dissociation and amyloid fibril formation induced by negatively charged membranes.Additional mechanisms for brain activation failure due to reduced glucose metabolism-a commentary on Zilberter and Zilberter: The vicious circle of hypometabolism in neurodegenerative diseases.Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase isoforms during neuronal apoptosis.Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.Glycolysis regulates pollen tube polarity via Rho GTPase signaling.
P2860
Q21145250-51943D0C-1587-4509-84A8-B988DFF107B8Q24545207-928357EA-3880-4333-98A2-8291298857D3Q27009552-298F075C-9F74-4913-A59A-AE2B0F60AE16Q27319514-CC264F7F-65F1-4FFD-877E-A1359B6AF347Q28256078-9A114C98-C60F-456A-A30F-9E9E5D1BF717Q28553472-9A11E3DB-63AD-4DD3-AD94-0E045C966EA9Q28748465-7402BECD-EC97-4018-87BB-218DF676A47EQ30319309-4BFF21F8-D401-4CB0-A397-899CA952FD4CQ30393354-7E74484C-0EDB-4BAE-A814-6A8617C2C346Q30659509-2930FB61-DC1B-4E79-AA03-F85AF688293BQ33921333-3FF5CC76-EF05-45D8-9EF5-02D9D0E61FEBQ33961380-58B89B99-F138-45F4-B738-A8DBED0C75EAQ34459681-A698C0D8-BDD6-4187-97A4-1C267C4D93ACQ35020178-8EA028B2-F037-4F22-B0D2-E483C84D7F57Q35548750-587B7A0F-93FC-4E1D-B880-9EE8DB90EAE3Q35709805-BA8BBD42-8105-4D58-A48A-87EB34BBBB95Q35919348-F130453B-C7A4-490F-9C35-7142805AE73AQ36301307-226591F0-7BD2-4FED-BA3C-DB7B2D263A73Q36421954-F33EA97C-0C28-4E2A-8166-F332B2A982E1Q36847277-4F1FE609-279B-4FE3-8106-9BE50260C2F8Q37114112-DD232344-CDED-4849-A1DF-8DD68CC9A792Q37131239-B838EA6B-5A7A-4D8B-A719-31D2C78EA2BFQ38094006-B46253D7-3E71-4B7B-B7AD-D6C94963CE01Q38603251-646294F2-0382-4B17-9E7A-825BAFAB1134Q39281845-722C53DD-B896-41BF-BAC9-0A3E2D414090Q39371468-4C481306-33FB-4B38-8545-050531DE22E2Q39719705-304000D0-D543-49BF-9FE3-7F129269E4F3Q40003995-82B0BB23-19DA-404C-91C0-12C3C2FDE011Q40290500-5889AB3C-473F-442B-BD2C-0BD4D92DF2F6Q42472756-6235C0D7-0300-483E-A804-45717EB208B8Q43078223-458BC664-7D21-417C-A01B-41E5FABDF977Q43223713-39F8A076-8D5A-4145-81C8-7273F462202EQ47990556-5F82FE17-BAEC-4B37-BC60-E07E2E73C5AFQ48275909-B8508980-0A67-4F41-A06A-9535BCEF86D5Q52889999-4CDBDB39-11F7-4686-9738-9A25AFA5CF1BQ54113913-14FA6819-7EA2-4E7E-B50E-77A7435461C7
P2860
Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@ast
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@en
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@nl
type
label
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@ast
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@en
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@nl
altLabel
Glyceraldehyde-3-phosphate Deh ...... nds CGP 3466 andR-(−)-Deprenyl
@en
prefLabel
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@ast
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@en
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@nl
P2093
P2860
P3181
P356
P1476
Glyceraldehyde-3-phosphate deh ...... ds CGP 3466 and R-(-)-deprenyl
@en
P2093
J van Oostrum
K Zimmermann
P Schindler
P Waldmeier
P2860
P304
P3181
P356
10.1074/JBC.273.10.5821
P407
P577
1998-03-06T00:00:00Z